Proven. Not Promised.
Aristotle is a panel for simultaneously screening for multiple cancers from a single blood sample. Aristotle has been built on the Sentinel Principle Technology Platform, which has already been used to develop one of the first commercially available blood tests for the Colorectal Cancer. ColonSentry® was validated in a 10,000 patient clinical trial and has been used in over 100,000 patients in North America to aid in the early detection of Colorectal Cancer.
Early Results Show that Aristotle has a high Sensitivity and Specificity across the following cancers.
Our scientists are also looking to apply Aristotle to multiple disease states in Gastroenterology, Neurology, Cardiology, and Autoimmune Disorders.
“GeneNews, one of the pioneers of the liquid biopsy, has developed the 'holy-grail' – a suite of tests that have the correct sensitivity and specificity to detect cancer early and perform correctly as a screening tool at the population level."
Former CEO and Founder, LifeX™
Professor of Human Genomics
Aristotle’s 2-fold Cross Validation & Accuracy
These graphs demonstrate Aristotle's high Sensitivity and Specificity on ten cancers.